CABIO(688089)2024-10-30 09:21Group 1: Company Overview - The company achieved a revenue of 387 million CNY in the first three quarters of 2024, representing a year-on-year growth of 19.19% [3] - The net profit attributable to shareholders was 83.89 million CNY, with a year-on-year increase of 38.86% [3] - The company focuses on synthetic biology technology, expanding into animal nutrition and personal care sectors [2] Group 2: Market Performance - Domestic market revenue share increased in the third quarter compared to international markets [3] - The company is benefiting from new national standards, the expiration of DSM patents, and the opening of international markets [2] Group 3: Product Development - The new synthetic biology product, 2'-fucosyllactose, has passed health committee review and obtained production licenses, currently in the final stages of production line debugging [3] - The company is actively expanding its product categories and application fields [2] Group 4: Operational Insights - The company's gross margin is influenced by product and customer structure changes, with higher margins in overseas markets [3] - Current production capacity utilization is at a high level, supported by two production bases in Wuhan and a new intelligent manufacturing system [3] - The northern production capacity is in trial production, awaiting customer validation [3]